Analysis of STRATA Skin Sciences (NASDAQ: SSKN) and Lucid Diagnostics (NASDAQ: LUCD)


STRATA Skin Sciences (NASDAQ:SSKN – Get Rating) and Lucid Diagnostics (NASDAQ:LUCD – Get Rating) are both small-cap medical companies, but which is the better company? We’ll compare the two companies based on institutional ownership strength, earnings, valuation, profitability, dividends, risk, and analyst recommendations.

Profitability

This table compares the net margins, return on equity and return on assets of STRATA Skin Sciences and Lucid Diagnostics.

Net margins Return on equity return on assets
STRATA Skin Sciences -8.78% -18.85% -9.87%
Clear diagnoses N / A N / A N / A

Benefits and evaluation

This table compares the revenue, earnings per share and valuation of STRATA Skin Sciences and Lucid Diagnostics.

Gross revenue Price/sales ratio Net revenue Earnings per share Price/earnings ratio
STRATA Skin Sciences $29.98 million 1.31 -$2.71 million ($0.08) -14.13
Clear diagnoses $500,000.00 209.37 -$28.08 million N / A N / A

STRATA Skin Sciences has higher revenues and profits than Lucid Diagnostics.

Institutional and insider ownership

37.5% of STRATA Skin Sciences shares are held by institutional investors. By comparison, 8.8% of shares in Lucid Diagnostics are held by institutional investors. 40.4% of STRATA Skin Sciences shares are held by insiders. Strong institutional ownership indicates that hedge funds, endowments, and large fund managers believe a stock will outperform the market over the long term.

Analyst Notes

This is a breakdown of recent recommendations and price targets for STRATA Skin Sciences and Lucid Diagnostics, as provided by MarketBeat.com.

Sales Ratings Hold odds Buy reviews Strong buy odds Rating
STRATA Skin Sciences 0 0 0 0 N / A
Clear diagnoses 0 0 6 0 3.00

Lucid Diagnostics has a consensus price target of $11.00, indicating a potential upside of 298.55%. Given Lucid Diagnostics’ possible higher upside, analysts clearly believe that Lucid Diagnostics is more favorable than STRATA Skin Sciences.

Summary

Lucid Diagnostics beats STRATA Skin Sciences on 6 out of 10 factors compared between the two stocks.

About STRATA Skin Sciences

(Get an assessment)

STRATA Skin Sciences, Inc., a medical technology company, develops, markets and markets products for the treatment of skin conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa and in Central and South America. The Company operates through two segments, Dermatology Recurrent Procedures and Dermatology Procedures Equipment. Its products include XTRAC and Pharos excimer lasers, VTRAC lamp systems and TheraClear treatment systems which are used for the treatment of psoriasis, vitiligo, acne and other skin conditions. The company distributes its products internationally through distributors and domestically directly to physicians. The company was formerly known as MELA Sciences, Inc. and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.

About Lucid Diagnoses

(Get an assessment)

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostic technology company. The company is focused on patients with gastroesophageal reflux, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, particularly a highly lethal esophageal adenocarcinoma. Its main products include EsoGuard, a laboratory-developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.



Get news and reviews for STRATA Skin Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for STRATA Skin Sciences and related companies with MarketBeat.com’s FREE daily newsletter.